Electrogastrogram (EGG) Reproducibility Study: EEG Readings in Normal Subjects and Dyspeptic Patients
NCT ID: NCT00220883
Last Updated: 2020-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2005-08-31
2006-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The secondary objective of this study is to determine whether the EGG readings are analyzed and diagnosed consistently when reviewed and compared by multiple blinded readers when the same tracing is reviewed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Study the EGG Abnormalities in Healthy Subjects and in Patients With Idiopathic and Diabetic Gastroparesis.
NCT05624034
Study of Gastric Motility in Eosinophilic Gastritis
NCT05229432
Pyloric Sphincter Abnormalities in Patients With Gastroparesis Symptoms
NCT04661215
HR-EGG in Medically Refractory Gastroparesis
NCT05789511
Evaluation of the Efficacy of Electroacupuncture in the Treatment of Functional Dyspepsia
NCT06618911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Each study subject/patient will have a total of two (2) EGGs with Water load tests performed for this study. Each EGG exam will be performed approximately one (1) week of each other, but no more than 4 weeks apart, and will be read in a blinded fashion by three (3) separate independent readers, in order to see if the readings are consistent with the previous readings that were obtained, as well as, by the readers themselves (Inter-reader rater reliability). Each reader will be blinded to the subject status (normal/healthy or patient) and also to the specific test they are reading (initial exam \[Visit 1\], or follow-up exam 1 week after Visit 1 \[Visit 2\]). All EGG exam results will be coded in order to keep them blind.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Normal healthy subjects with no signs or symptoms of gastrointestinal discomfort.
1. Male or female patients who are 18 to 72 years of age.
2. Patients who present with varying gastric complaints of discomfort
3. Patients who meet all Rome II criteria for functional dyspepsia (see Rome II criteria checklist)
Concomitant medications are allowed during the study period.
Exclusion Criteria
1. \< 18 years of age or \>72 years of age
2. Subjects with known gastrointestinal or liver cancers, pancreaticobiliary tract diseases, active peptic ulcer disease or uncontrolled lactose intolerance.
3. Subjects with cardiovascular, pulmonary disorders, or subjects with diabetes mellitus, a malignancy or who are known to be HIV positive.
4. Subjects with a history of gastric, intestinal or colonic resections. Subjects who are at less than a three month status for either: post appendectomy, cholecystectomy, or hysterectomy with or without oophorectomy.
5. Subjects who are unable to give informed consent or adequately express their subjective complaints.
6. Subjects who abuse drugs or alcohol.
7. Female subjects who are pregnant.
For functional dyspepsia patients:
18 Years
72 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Temple University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Henry P Parkman, MD
Role: PRINCIPAL_INVESTIGATOR
Temple University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Temple University School of Medicine
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TU4687
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.